
Gilda Da C Santos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/276352/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in populationâ€based reflex testing. Cancer, 2019, 125, 4043-4051.	4.1	14
2	The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. Cancer Cytopathology, 2019, 127, 72-78.	2.4	10
3	FTA Cards for Preservation of Nucleic Acids for Molecular Assays: A Review on the Use of Cytologic/Tissue Samples. Archives of Pathology and Laboratory Medicine, 2018, 142, 308-312.	2.5	31
4	Cytological preparations for molecular analysis: A review of technical procedures, advantages and limitations for referring samples for testing. Cytopathology, 2018, 29, 125-132.	0.7	30
5	Translation of Knowledge to Practice—Improving Awareness in NSCLC Molecular Testing. Journal of Thoracic Oncology, 2018, 13, 1004-1011.	1.1	8
6	Preanalytic specimen triage: Smears, cell blocks, cytospin preparations, transport media, and cytobanking. Cancer Cytopathology, 2017, 125, 455-464.	2.4	60
7	Use of cytological samples of metastatic melanoma for ancillary studies. Cytopathology, 2017, 28, 221-227.	0.7	9
8	Performance of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Diagnosis of Isolated Mediastinal and Hilar Lymphadenopathy. Respiration, 2017, 94, 457-464.	2.6	26
9	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	2.4	58
10	Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario. Current Oncology, 2017, 24, 103-110.	2.2	30
11	Mantle cell lymphoma involving the thyroid: a case report. Cytopathology, 2016, 27, 289-292.	0.7	4
12	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1267-1272.	2.5	95
13	A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. Journal of Clinical Pathology, 2016, 69, 607-611.	2.0	15
14	Molecular Techniques and Methods Applied in Cytology. Essentials in Cytopathology Series, 2016, , 17-25.	0.1	2
15	Preanalytic parameters in epidermal growth factor receptor mutation testing for non–small cell lung carcinoma: A review of cytologic series. Cancer Cytopathology, 2015, 123, 633-643.	2.4	40
16	Cell blocks for subtyping and molecular studies in nonâ€small cell lung carcinoma. Cytopathology, 2015, 26, 331-333.	0.7	1
17	Multiplex sequencing for <i>EZH2</i> , <i>CD79B</i> , and <i>MYD88</i> mutations using archival cytospin preparations from Bâ€cell nonâ€Hodgkin lymphoma aspirates previously tested for <i>MYC</i> rearrangement and <i>IGH/BCL2</i> translocation. Cancer Cytopathology, 2015, 123, 413-420.	2.4	15
18	Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Annals of Oncology, 2015, 26, 1415-1421.	1.2	187

GILDA DA C SANTOS

#	Article	IF	CITATIONS
19	Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Lung Cancer, 2015, 89, 110-114.	2.0	17
20	Epstein-Barr virus encoded RNA detected byin situhybridization using cytological preparations. Cytopathology, 2014, 25, 101-107.	0.7	16
21	Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing. Journal of Thoracic Oncology, 2014, 9, 947-956.	1.1	72
22	Cytomorphological and clinicopathological spectrum of pulmonary marginal zone lymphoma: the utility of immunophenotyping, <scp>PCR</scp> and <scp>FISH</scp> studies. Cytopathology, 2014, 25, 250-258.	0.7	11
23	A targeted intervention to improve awareness to molecular testing in NSCLC Journal of Clinical Oncology, 2014, 32, 6547-6547.	1.6	1
24	Diagnosis and subclassification of lymphomas and nonâ€neoplastic lesions involving mediastinal lymph nodes using endobronchial ultrasoundâ€guided transbronchial needle aspiration. Diagnostic Cytopathology, 2013, 41, 1023-1030.	1.0	63
25	"The petals and thorns―of ROSE (rapid onâ€site evaluation). Cancer Cytopathology, 2013, 121, 4-8.	2.4	87
26	ROSEs (Rapid onâ€site evaluations) to our patients: The impact on laboratory resources and patient care. Cancer Cytopathology, 2013, 121, 537-539.	2.4	13
27	Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. Lung Cancer, 2013, 79, 215-220.	2.0	30
28	Minimizing delays in DNA retrieval: The "freezer method―for glass coverslip removal. Letter to the editor regarding comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathology, 2013, 121, 533-533.	2.4	24
29	<scp><i>EZH2</i></scp> and <scp><i>CD79B</i></scp> mutational status over time in Bâ€cell nonâ€Hodgkin lymphomas detected by highâ€throughput sequencing using minimal samples. Cancer Cytopathology, 2013, 121, 377-386.	2.4	26
30	Cytological preparations for molecular pathology. Cancer Cytopathology, 2013, 121, 275-275.	2.4	2
31	Training in molecular cytopathology. Cytopathology, 2013, 24, 205-207.	0.7	0
32	Standardizing preanalytical variables for molecular cytopathology. Cancer Cytopathology, 2013, 121, 341-343.	2.4	29
33	Subclassification of lymphoproliferative disorders in serous effusions. Cancer Cytopathology, 2013, 121, 261-270.	2.4	26
34	Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer Journal of Clinical Oncology, 2013, 31, e19032-e19032.	1.6	0
35	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology, 2012, 30, 3002-3011.	1.6	229
36	Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: Review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. Lung Cancer, 2012, 77, 501-506.	2.0	41

GILDA DA C SANTOS

#	Article	IF	CITATIONS
37	Negative images of crystalline immunoglobulin in crystal storing histiocytosis: A potential cytologic mimic of mycobacteria in smears. Diagnostic Cytopathology, 2012, 40, 916-919.	1.0	12
38	The use of FTA cards for preserving unfixed cytological material for highâ€ŧhroughput molecular analysis. Cancer Cytopathology, 2012, 120, 206-214.	2.4	36
39	A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1393-1400.e1.	0.8	484
40	EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 49-69.	22.4	644
41	<i>ECFR</i> gene status in cytological samples of nonsmall cell lung carcinoma. Cancer Cytopathology, 2011, 119, 80-91.	2.4	107
42	Cytomorphologic findings of Bâ€cell lymphomas with concurrent <i>IGH/BCL2</i> and <i>MYC</i> rearrangements (dualâ€translocation lymphomas). Cancer Cytopathology, 2011, 119, 254-262.	2.4	11
43	Maximizing the yield of lymph node cytology. Cancer Cytopathology, 2011, 119, 361-366.	2.4	25
44	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	4.1	143
45	Classifying Bâ€cell nonâ€Hodgkin lymphoma by using MIBâ€1 proliferative index in fineâ€needle aspirates. Cancer Cytopathology, 2010, 118, 166-172.	2.4	26
46	Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations. Cancer Cytopathology, 2010, 118, 250-258.	2.4	49
47	Detection of <i>EGFR</i> and <i>KRAS</i> mutations in fineâ€needle aspirates stored on Whatman FTA cards. Cancer Cytopathology, 2010, 118, 450-456.	2.4	46
48	FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. Journal of Clinical Pathology, 2010, 63, 630-634.	2.0	83
49	The role of fine-needle aspiration in the diagnosis of thyroid lymphoma: a retrospective study of nine cases and review of published series. Journal of Clinical Pathology, 2010, 63, 129-133.	2.0	36
50	Penile metastasis of urothelial carcinoma diagnosed by fine-needle aspiration. CytoJournal, 2009, 6, 10.	1.7	5
51	Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	1.6	674
52	Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10155-10160.	7.1	64
53	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. Journal of Clinical Oncology, 2007, 25, 2184-2190.	1.6	92
54	The Association of p16INK4A and Fragile Histidine Triad Gene Expression and Cervical Lesions. Journal of Lower Genital Tract Disease, 2007, 11, 151-157.	1.9	3

GILDA DA C SANTOS

#	Article	IF	CITATIONS
55	Inter―and intraobserver reproducibility of thyroid fine needle aspiration cytology: an analysis of discrepant cases. Cytopathology, 2007, 18, 105-111.	0.7	58
56	Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genetics and Cytogenetics, 2007, 179, 102-111.	1.0	20
57	Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer. Journal of Clinical Oncology, 2007, 25, 7571-7571.	1.6	18
58	Fine-needle aspiration cytology in the diagnosis of superficial lymphadenopathy: a 5-year Brazilian experience. Diagnostic Cytopathology, 2006, 34, 130-134.	1.0	18
59	Immunocytochemical Expression of p16INK4A and Ki-67 in Cytologically Negative and Equivocal Pap Smears Positive for Oncogenic Human Papillomavirus. International Journal of Gynecological Pathology, 2005, 24, 118-124.	1.4	49
60	Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144.	27.0	1,787
61	Inflammatory fibroid polyp: an immunohistochemical study. Arquivos De Gastroenterologia, 2004, 41, 104-107.	0.8	24
62	lmunoexpressão da proteÃna Her-2 em punção aspirativa com agulha fina de carcinoma de mama: correlação com os achados da peça cirúrgica. Revista Brasileira De Ginecologia E Obstetricia, 2003, 25, 23-28.	0.8	1
63	Sistemas de graduação para carcinoma de mama: estudo comparativo da concordância cito-histológica. Revista Brasileira De Ginecologia E Obstetricia, 2003, 25, .	0.8	1
64	Estudo do raspado de conjuntiva e margem palpebral de pacientes tratados de retinoblastoma: etapa I - Microflora aeróbica. Arquivos Brasileiros De Oftalmologia, 2002, 65, 217-222.	0.5	0
65	Estudo do raspado de conjuntiva de pacientes tratados de retinoblastoma: Etapa II citologia. Arquivos Brasileiros De Oftalmologia, 2002, 65, 305-310.	0.5	0
66	A clinicopathologic study of 196 intraoral minor salivary gland tumours. Journal of Oral Pathology and Medicine, 1999, 28, 264-267.	2.7	134
67	Computed tomography-guided fine-needle aspiration biopsy. Sao Paulo Medical Journal, 1997, 115, 1343-1348.	0.9	0
68	Acinic cell carcinoma arising in nasal cavity: Diagnosis by fine-needle aspiration. Diagnostic Cytopathology, 1994, 10, 96-97.	1.0	7